Unknown

Dataset Information

0

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (Mpro, also called 3CLpro) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 Mpro and its complex with an α-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 Mpro The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC7164518 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.

Zhang Linlin L   Lin Daizong D   Sun Xinyuanyuan X   Curth Ute U   Drosten Christian C   Sauerhering Lucie L   Becker Stephan S   Rox Katharina K   Hilgenfeld Rolf R  

Science (New York, N.Y.) 20200320 6489

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M<sup>pro</sup>, also called 3CL<sup>pro</sup>) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M<sup>pro</sup> and its complex with an α-ketoamide inhibitor. This was d  ...[more]

Similar Datasets

Unknown COVID-19: In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2.
| S-EPMC8205609 | biostudies-literature
Unknown Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of α-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2.
| S-EPMC7688048 | biostudies-literature
Unknown An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.
| S-EPMC7695570 | biostudies-literature
Unknown Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.
| S-EPMC8056153 | biostudies-literature
Unknown Convergent synthesis of alpha-ketoamide inhibitors of Pin1.
| S-EPMC2844255 | biostudies-literature
Unknown De novo Design of SARS-CoV-2 Main Protease Inhibitors.
| S-EPMC8916680 | biostudies-literature
Unknown Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.
| S-EPMC8491553 | biostudies-literature
Unknown Fragment-based in silico design of SARS-CoV-2 main protease inhibitors.
| S-EPMC8444677 | biostudies-literature
Unknown Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
| S-EPMC11459967 | biostudies-literature
Unknown Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
| S-EPMC7462840 | biostudies-literature